Latest! Top 15 Chinese Pet-Related Listed Companies by Revenue

Statistical scope: Revenue from pure pet-related business of listed companies. Data source: Semi-annual reports (2026 H1) of pet-related listed companies / pet-related business segments of listed companies. Among these 15 enterprises, most achieved high revenue growth; however, the majority also reported declining net profits. Among those publicly disclosing net profit data, only Youpai Co., Ltd. posted a nearly 36% net profit increase—emerging as the standout 'dark horse'. Pet food segment: Strong growth in staple food sales fails to offset profit erosion. Guai Bao Pet reported H1 revenue of RMB 3.543 billion, up 10.01% year-on-year; yet attributable net profit stood at merely RMB 191 million—a sharp 49.57% decline year-on-year. The profit slump stemmed primarily from sustained investment in brand building and channel expansion. Cost of sales rose 15.14%, outpacing revenue growth; sales expenses reached RMB 860 million, up 26.43% year-on-year; financial expenses turned positive—from negative to RMB 35.6885 million. Growth highlights include: staple food revenue hit RMB 2.332 billion, up 23.87% year-on-year, significantly increasing its share of total operating revenue. The company filed 25 patents during H1 and launched the professional clinical nutrition brand "Kangfu", establishing an integrated “education + product + tools” medical-food collaboration model. Zhongchong Co., Ltd. reported H1 revenue of RMB 3.281 billion, up 34.88% year-on-year—the fastest growth among pet food firms; yet attributable net profit was only RMB 127 million, down 37.63% year-on-year. Exchange losses, rising raw material costs, and intensified investment in proprietary brand promotion weighed on profitability. Sales expenses surged 46.34% to RMB 435 million; financial expenses skyrocketed 1235.56% to RMB 31.8841 million. Highlights: both pet snacks and staple food delivered strong growth; new categories performed exceptionally well. Specifically, pet snacks contributed ~RMB 2.055 billion—62.65% of total revenue—and grew 34.37% year-on-year; staple food generated ~RMB 998 million—30.41% of total revenue—and rose 27.33% year-on-year; pet supplies and other businesses brought in RMB 227 million—6.94% of total revenue—with an impressive 91.06% year-on-year growth. Proprietary brands continued gaining traction, with notable success in brand upgrading. Peidi Co., Ltd. reported H1 revenue of RMB 735 million, up only 0.96% year-on-year—essentially flat. Attributable net profit plunged 69.25% to RMB 24.3207 million. Basic EPS dropped from RMB 0.32 to RMB 0.10 year-on-year. Net profit nearly collapsed—squeezed by dual pressure on cost and expense fronts. Financial expenses surged 728.77% year-on-year, adding RMB 26.3816 million. Highlights: staple food and wet food revenue reached RMB 59.26 million, up 30.68% year-on-year—the fastest-growing category—reflecting early success of the company’s strategic shift toward full-category development (“snacks + staple food”). Plant-based chewables generated RMB 258 million, up 16.89% year-on-year, with a gross margin of 28.76%, becoming the company’s largest category. Domestically, the Jueyan brand maintained steady revenue growth, demonstrating robust competitiveness and effective brand renewal in the domestic market. Lusi Co., Ltd. reported H1 revenue of RMB 493 million, up 26.17% year-on-year—a solid growth rate; yet attributable net profit declined 18.56% to RMB 24.8077 million.

Latest Top 10 Chinese Pet-Related Listed Companies by Revenue: Who Is the Most Profitable?

Secondly, product portfolio optimization continues lifting the share of high-value-added categories. The company’s ODM model is transitioning from ‘scale-driven’ to ‘value-driven’. Its proprietary brand ‘Jueyan’ achieved GMV growth of 52% and 30% year-on-year during the 618 and Double Eleven shopping festivals, respectively. Facing tariff uncertainty, Peidi Co., Ltd. is actively expanding into high-potential new markets—including Europe and Canada—to diversify reliance on any single market. Lusi Co., Ltd. reported 2025 revenue growth of 10.46% to RMB 859 million, while attributable net profit fell 22.85% to RMB 60.4596 million. Initial low capacity utilization at its Cambodian subsidiary led to temporary losses; meanwhile, although domestic staple food sales rose 40.02%, declining gross margins for jerky products and reduced foreign exchange gains jointly dragged down overall net profit. Looking ahead, Lusi plans to gradually raise the Cambodian subsidiary’s capacity utilization to a healthy level to offset initial investment burdens. Langnuo Pet, specializing in freeze-dried pet food, reported revenue of RMB 292 million—up 26.47% year-on-year—but net profit edged down 4.93% to RMB 31.8395 million. Still, given its robust revenue growth and only marginal profit dip, its premium pricing power in the high-value-added freeze-dried market remains largely intact. Chaoyun Group leverages its household care core business, with pet-related operations emerging as its fastest-growing engine. In 2025, pet-related revenue reached RMB 222 million—up 74.3% year-on-year; gross margin stood at a high 60%, up 5.3 percentage points year-on-year; offline pet stores expanded to 73 locations. In the pet sector, Chaoyun Group pursues a dual-driver strategy: “store expansion + proprietary product upgrades”. Its brand portfolio includes the “Mile Guiguai” and “Zhua Zhua” chain brands, covering cities including Guangzhou, Shenzhen, Foshan, and Suzhou. Keao Co., Ltd., primarily engaged in disposable hygiene products, generated RMB 70.4541 million in pet hygiene product revenue—up 2.11% year-on-year—accounting for only 6.13% of total revenue. Though growth is modest, the company continues broadening its coverage of diversified consumption needs for pet-owning families via a “proprietary brand + ODM” model. Pet healthcare & veterinary pharmaceuticals: second growth curve—high growth and countercyclical resilience Unlike pet food and supplies, pet healthcare and veterinary pharmaceuticals demonstrate exceptional growth momentum and profit resilience—driven by high R&D barriers and surging demand for pet medical services. RuiPu Biological Technology is one of the most comprehensively positioned animal health enterprises in the pet segment. In 2025, its attributable net profit totaled RMB 401 million—up 33.18% year-on-year—while pet-related revenue reached RMB 858 million, up 24.39% year-on-year. Its pet business comprises two core segments: pet supply chain revenue of RMB 782 million (up 23.42% year-on-year) and proprietary pet vaccines & pharmaceuticals revenue of RMB 76.41 million (up 35.33% year-on-year). Its pet supply chain channels now cover over 14,000 pet medical terminals nationwide and partner with more than 300 domestic and international pet healthcare brands—evolving comprehensively from “distributor → brand operator → solutions provider”. On the proprietary product front, the company has secured 19 new veterinary drug registrations for pets, achieving comprehensive coverage across deworming, anesthesia & analgesia, and ear treatments.

Oil-Dri Corporation of America (ODC) Among Best Pet Care Stocks for Consistent Recurring Revenue

Jun 22, 2026

Oil-Dri Corporation reported a 9% increase in third-quarter consolidated net sales and a 25% rise in net income. The board approved a 10% dividend increase and authorized share repurchases of up to 500,000 shares.

Yahoo Finance

2026-03-25

Oil Dri declares $0.205 dividend

2026-03-25

Oil-Dri Q1 Earnings Decline Year-Over-Year Amid Tough Comparison Pressures

2026-04-03

Oil-Dri Updates Deferred Compensation Plan and Restricted Stock Agreements

2026-04-03

Oil-Dri Corporation of America Insiders Dispose Stock Amid Bearish Signals

2026-04-04

Oil-Dri Corporation Share Price Crosses Above 200-Day Moving Average